|
|
News Breaks | | | | September 12, 2012 | | 07:03 EDT |  | ONCY | Oncolytics Biotech provides update on Phase III trial of Reolysin
The company has conducted an internal analysis of the blinded combined clinical data for all 80 patients enrolled in the first stage of the study. The study remains blinded at this time. At the time of the analysis, 23 patients of the 80 had not yet progressed but were included for the purposes of analysis. The median evolving progression free survival of the 80 patients was greater than expected, as was the best response rate. On further examination, it was observed that patients for whom only metastatic disease was being measured by clinicians, were responding differently to treatment than patients who had local regional head and neck disease. Patients in whom only metastatic disease was measured had a median evolving PFS of 120 days, which was statistically significantly greater than those patients with a noted local regional head and neck tumor. | |
|
News For ONCY From The Last 14 Days Check below for free stories on ONCY the last two weeks. |
|
|
| There are no results for ONCY |
|
|
|
|
|
|
